Use caution Drug recall · FDA · Published March 24, 2022

Preferred Pharma Recalls Diclofenac Sodium Topical Solution Due to CGMP Deviations

Preferred Pharmaceuticals recalls 528 bottles of Diclofenac Sodium Topical Solution due to CGMP deviations. Check lot numbers and expiration dates for affected units.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0773-2022Drug Preferred Pharmaceuticals ›

Use caution until it’s fixed

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Take action

Contact the company

Recalling firmPreferred Pharmaceuticals, Inc.1250 N Lakeview Ave Ste O · Anaheim, CA 92807-1801

✎ GovInfoNow plain-language explainer

Preferred Pharmaceuticals, Inc. is recalling 528 bottles of Diclofenac Sodium Topical Solution 1.5% w/w because of Current Good Manufacturing Practice (CGMP) deviations. The manufacturer, Teligent Pharma, Inc., is discontinuing its stability study program for all products within their expiry dates. This recall affects specific lots distributed nationwide in the USA. Read more at govinfonow.com/recall/35049-preferred-pharma-recalls-diclofenac-sodium-topical-solution-due-to-cgmp.

Source Summary by GovInfoNow · govinfonow.com/recall/35049-preferred-pharma-recalls-diclofenac-sodium-topical-solution-due-to-cgmp · Updated October 10, 2026 · FDA enforcement record: FDA #D-0773-2022

Cite this page

“Preferred Pharma Recalls Diclofenac Sodium Topical Solution Due to CGMP Deviations.” GovInfoNow, updated October 10, 2026. https://govinfonow.com/recall/35049-preferred-pharma-recalls-diclofenac-sodium-topical-solution-due-to-cgmp. Based on FDA recall #D-0773-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0773-2022%22&limit=1).

The FDA announced on March 24, 2022, that Preferred Pharmaceuticals, Inc. is recalling Diclofenac Sodium Topical Solution due to current Good Manufacturing Practice (CGMP) deviations. The firm initiated the voluntary Class II recall because manufacturer Teligent Pharma, Inc. is discontinuing its stability study program.

How to tell if you have it

Brand: Preferred Pharmaceuticals
Product: Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid
Size: 150 ml bottle
NDC: 68788-7918-01
Lots: E1220B (Exp. 01/31/2023), F0220M (Exp. 3/31/2023), F2320A (Exp. 3/31/2023), F3020M (Exp. 3/31/2023), G0920Q (Exp. 3/31/2023), C0821M (Exp. 1/31/2024), J1920 (Exp. 5/31/2023), E2421j (Exp. 4/30/2024)
Distribution: Nationwide within the USA
Units affected: 528 bottles

The hazard

The recall covers all products within their expiry dates because Teligent Pharma, Inc. is discontinuing its stability study program. The FDA classified this as a Class II recall due to CGMP deviations.

Context

GovInfoNow's records show Preferred Pharmaceuticals, Inc. has 32 other recalls on record since August 15, 2018. Other recent recalls of similar products include Preferred Pharma Recalls Lidocaine Ointment Due to Content Issues (September 28, 2026), Geri-Care Eye Drops Recalled for Sterility Risk (March 25, 2026), and Preferred Pharma Recalls Ondansetron ODT Due to Defective Seals (November 17, 2025). Other recent recalls of similar products include Wells Pharma Fentanyl Citrate Injectable Solution Recall: Cgmp Deviations (April 1, 2026), Wells Pharma Fentanyl Citrate Solution Recall: CPG Deviations (April 1, 2026), and Ajanta Pharma Fenofibrate Capsules Recall: CGMP Deviations Risk (May 28, 2026).

How to tell if you have this one

Look for a 150 ml bottle labeled as Diclofenac Sodium Topical Solution 1.5% w/w, Generic for Pennsaid, Rx Only, manufactured by Sola Pharmaceutical or Preferred Pharmaceuticals, Inc. Check the NDC 68788-7918-01 and verify if your lot number is one of: E1220B, F0220M, F2320A, F3020M, G0920Q, C0821M, J1920, or E2421j.

Brand
Preferred Pharmaceuticals
Category
Drug

Based on the official FDA remedy

What to do — step by step

Check Your Bottle
Verify if your bottle matches the NDC 68788-7918-01 and has one of the recalled lot numbers with expiration dates ranging from January 2023 to April 2024.
Consult Your Pharmacist
Contact your pharmacy or healthcare provider immediately to discuss alternative treatments or return options, as the record does not specify a direct remedy from the manufacturer.

Where it went and when

Where it was distributed

Distributed nationwide.

FDA distribution: “Nationwide within the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 19 months after the firm started it.

Mar 24, 2022Firm started the recall
Apr 15, 2022FDA classified it Class II
Apr 27, 2022Published in FDA’s Enforcement Report
Oct 25, 2023FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Other Preferred Pharmaceuticals recalls

Latest drug recalls

Keep exploring

Link to this recall

<a href="https://govinfonow.com/recall/35049-preferred-pharma-recalls-diclofenac-sodium-topical-solution-due-to-cgmp">Preferred Pharma Recalls Diclofenac Sodium Topical Solution Due to CGMP Deviations (GovInfoNow)</a>

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

Official source: FDA Recall #D-0773-2022 (March 24, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0773-2022 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 10, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.